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Progressive bronchiectasis and CMC in a patient with 
STAT1 GOF — a rare case of primary immunodeficiency
Abstract
Bronchiestasis is a common complication developing in patients with primary immunodeficiency disorders. AD GOF STAT1 defi-
ciency is characterized by CMC, repeated infections, and autoimmunity. It is the most frequently diagnosed entity in a group of 
PIDs with CMC. Here, we present the first Polish case of a female patient with early-onset bronchiestasis accompanied by CMC 
and a severe course of infections who was genetically diagnosed with AD GOF1 STAT1 mutation at the age of 15.
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Introduction
Bronchiectasis is a chronic respiratory di-
sease characterized by an abnormal permanent 
dilation of the bronchi which are typically 
described as cylindrical, varicose, or cystic in 
appearance. The condition is characterized by 
a vicious cycle of persistent bacterial infec-
tions and excessive neutrophilic inflammation 
leading to the impairment of airway defence 
mechanisms. Risk factors for bronchiectasis are 
listed in Table 1 [1]. Appropriate baseline inve-
stigations include a chest radiograph, pulmonary 
function tests (PFT), and sputum bacteriological 
cultures. However, the gold standard for confir-
ming the diagnosis is high-resolution computed 
tomography (HRCT) of the chest. The main aims 
of management are to reduce symptoms and 
exacerbation frequency and severity, to preserve 
lung function, and to improve the patient’s heal-
th-related quality of life [2]. 
Bronchiectasis is also a well-recognized com-
plication of primary antibody deficiencies (PAD), 
which are the most frequently diagnosed primary 
immunodeficiency disorders (PID). PAD patients 
share a significant susceptibility to respiratory di-
seases that represent a relevant cause of morbidity 
and mortality. Pulmonary complications include 
acute and chronic infection-related diseases such 
as pneumonia and bronchiectasis, and immune-
mediated interstitial lung diseases such as gra-
nulomatous-lymphocytic interstitial lung disease 
(GLILD) and cancer [3]. A recent review of the UK 
PID Registry data showed that 47% of a cohort 
of 801 patients with primary hypogammaglobu-
linemia had bronchiectasis confirmed by HRCT 
[4]. Unfortunatelly, lung disease can progress in 
PID patients despite conventional treatment with 
immunoglobulin G (IgG) replacement therapy 
and/or antibiotic prophylaxis [4].
High susceptibility to mucosal and skin 
candidiasis is a hallmark of several PIDs as-
sociated with impaired interleukin-17 (IL-17) 
T  cell immunity. Isolated chronic mucocuta-
neous candidiasis (CMC) was first described in 
the 1960s, but its genetic causes are still being 
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investigated. In 2011, a group of scientists from 
the Laboratory of Human Genetics of Infectious 
Diseases (Necker Hospital, Paris) reported 47 pa-
tients with autosomal dominant (AD) CMC from 
20 kindreds with 12 gain-of-function (GOF) mu-
tations in the signal transducer and activator of 
transcription 1 (STAT1) gene [5].
Case report
Here, we report the first Polish case of 
a 19-year-old female with a STAT1 GOF path-
ogenic variant who presented with recurrent 
respiratory bacterial infections complicated by 
CMC and severe bronchiectasis. She was born as 
a second child to young, healthy and unrelated 
parents after an uneventful pregnancy and deli-
very, and without a family history of recurrent in-
fections. She received the BCG vaccine during the 
first days of life. At the 2nd week of age, she was 
treated with intravenous antibiotics due to mul-
tiple abscesses of the scalp. During her first year 
of life, she was hospitalized for pneumonia twice 
with accompanied persistent oral thrush (Candi-
da glabrata) and severe malnutrition. Infection 
with typical and atypical bacteria, viruses (CMV), 
alpha-1 antitrypsin deficiency, cystic fibrosis, 
and congenital malformations of the respiratory 
system were excluded. Performed chest computed 
tomography (CT) revealed inflammatory changes 
with atelectasis in segment (S) 2 and in the lower 
lobe of the right lung. Despite the fact that the 
presence of acid-fast bacilli (AFB) in bronchial la-
vage was not confirmed, clinical course indicated 
tuberculosis. During anti-mycobacterial therapy 
(rifampicin — RMP, isoniazid — INH, strepto-
mycin — SM, pyrazinamide — PZA) lasting for 
6 months, systematic clinical improvement was 
observed with resolution of inflammatory lesions 
in a second chest CT. At the age of 4, another chest 
CT was performed due to a chronic cough and 
periodic bronchopulmonary exacerbations. The 
results of this CT showed a progression of chan-
ges including linear densities in S1 and S2 of the 
right lung, bilateral striatal-atelectical lesions in 
S4 and S5, thickening of bronchial walls, and 
bronchiectasis in S8, S9, and S10 of the left lung. 
Colonization of airways with Pseudomonas aeru-
ginosa and methicillin-resistant Staphylococcus 
aureus (MSSA) has been observed since then. 
Since the age of 7, the patient has been suspected 
of having PID with CMC. Physical examination 
revealed severe body mass and growth delay (BMI 
13 kg/m2), clubbing, oral thrush, dental caries, 
splenomegaly, as well as crackling and rhonchi 
over both lungs. Immunological tests showed 
IgA, IgG2, and IgG4 deficiency, mild CD4+ lym-
phopenia, reversed CD4/CD8 ratio, and a very 
low percentage and count of CD19+ cells (Table 
2). Initially, common variable immunodeficiency 
(CVID) was suspected. This was then changed 
to combined immunodeficiency (CID) and in-
travenous immunoglobulin supplementation 
(IVIG), antibiotic and antifungal prophylaxes 
were recommended. Despite state-of-the-art 
treatment, the patient still suffered from severe 
recurrent bacterial and muco-cutaneous fungal 
(Candida spp) infections. Destructive changes 
in the respiratory tract continued.  At the age of 
10, she was operated on to treat a severe hiatus 
hernia. Progressive esophageal obstruction as-
sociated with post-inflammatory stenosis of the 
esophagus (most likely a consequence of chronic 
candidiasis) required numerous esophageal di-
latations. At the age of 13, molecular tests were 
performed in the Necker Hospital in Paris. Two 
years later, we were informed about heterozy-
gous missense mutations in STAT1 leading to 
deleterious amino acid substitutions in the DNA 
binding domain (P1: c.1154C >  T; p.T385M) 
which provided us with a definitive diagnosis 
for the patient. The parents of the patient were 
not genetically evaluated. At the age of 15, she 
Table 1. Causes of bronchiectasis with focus on primary 
immunodeficiencies
Cause Mean incidence
Primary immunodeficiency disorders
 — common variable immunodeficiency 
(CVID)
 — agamaglobulinaemia (XLA and AR)
 — hyper-IgM syndromes (HIGM)
 — autosomal dominant Hyper-IgE Syn-
drome (AD HIES)
1.1–16.0%
Cystic fibrosis 0.6–2.7%
Alpha-1 antitrypsin deficiency 0.6–11.3%
Primary ciliary dyskinesia 2.0–10.3%
Allergic bronchopulmonary aspergillosis 0.9–7.8%
Autoimmune/connective tissue diseases 
(typically rheumatoid arthritis, SLE)
1.8–31.1%
Inflammatory bowel diseases 1.0–3.0%
Congenital malformations 0.2–0.6%
Aspiration 0.2–11.3%
Postinfectious 29.0–42.0%
Idiopathic* 26.0–53.0%
*Other causes excluded
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developed a severe invasive skin and pulmonary 
bacterio-fungal infection which was resistant to 
fluconazole. Chronic treatment with voriconazole 
has been implemented since then. At this time, 
CT scans show a significant degree of cylindrical 
and cistic bronchiectases in both lungs (Figure 
1). Due to hypothyroidism, supplementation of 
thyroid hormones was incorporated. During the 
11-year-follow-up, PFTs were repeatedly perfor-
med and an obstructive ventilatory pattern was 
present increasing airway resistance. Air trapping 
was gradually worsening. However, difficult co-
operation of the patient influcenced PFT quality 
and brought interpreting difficulties.
At the age of 16, hematopoietic stem cell 
transplantation (HSCT) was considered due to 
a progressively deteriorating clinical and im-
munological condition of the patient (Table 2). 
However, the unwillingness of patient and her 
parents towards the procedure together with 
severe lung disease and the poor worldwide 
success rates of HSCT discouraged us from this 
decision. Currently, the patient is treated with 
subcutaneous immunoglobulins (SCIG), an an-
tifungal agent (voriconazole), and antibacterials 
(Co-trimoxazole, macrolides, inhaled colistine) 
for prophylaxis.
Discussion
STAT1 is the target of heritable loss-of-func-
tion (LOF) or gain-of-function (GOF) muta-
tions that give rise to distinct clinical phenoty-
pes. STAT1 mediates the actions of many cyto-
kines involved in mounting innate and adaptive 
immune responses to viruses and intracellular 
bacteria [5, 6]. Recurrent bacterial infections are 
common to both types of STAT1 mutations. AR 
Figure 1. High-resolution computed tomography of the chest. A. Frontal plane; B. Cystic bronchiectasis with thickening of bronchial walls; C. Sac-
cular dilatation of bronchi, partly with mucoid impaction in some places; D. three-dimensional imaging — a significant degree of cylindrical and 
cystic bronchiectasis in both lungs
A
C
B
D
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LOF mutations are additionally defined by inva-
sive mycobacteriosis and viral infections, espe-
cially Herpesviridae (HSV, CMV, EBV), whereas 
AD LOF mutations present with susceptibility 
to mycobacteria but normal immunity against 
viruses. AD GOF mutations are distinguished by 
chronic mucocutaneous candidiasis and autoim-
munity [5, 7].
GOF mutations in STAT1 have increasingly 
been identified as a genetic cause of AD CMC 
which impaires the development of IL-17-pro-
ducing T cells [5, 6]. CMC is a heterogeneous 
disorder with recurrent chronic Candida spp 
infections primarily involving the nails, skin, and 
oropharynx. CMC can be associated with various 
pathological conditions listed in Table 3. Recent 
studies have demonstrated that the clinical spec-
tra of STAT1 GOF mutations continue to expand 
encompassing bronchiectasis, immune dysregu-
lation, and combined immunodeficiency [8, 9]. 
Disease manifestations of GOF STAT1 can be mild 
or severe and life-threatening [9, 10]. 
Here, we describe a patient with STAT1 GOF 
mutations who experienced poor weight gain, 
chronic refractory candidiasis, recurrent pneumo-
nia resulting in bronchiectasis, and severe oral 
and esophageal candidiases with strictures asso-
ciated with hypothyroidism. The clinical picture 
of our patient was consistent with a combined 
immunodeficiency phenotype resembling a few 
cases reported in literature [11, 12]. The authors 
described two patients presenting in early infancy 
with candidiasis and chronic lung findings inclu-
ding bronchiectasis. One of them also developed 
a mycobacterial infection. 
STAT1 GOF mutations may present early 
in life with very complex and variable phenoty-
pes. Patients, in most cases, suffer from persistent 
and recurrent infections of the skin, nails, and 
mucosa, mainly caused by C. albicans, variably 
associated with bacterial (i.e., respiratory tract and 
skin), viral (i.e., mostly Herpesviridae), and, less 
frequently, with mycobacterial infections. They 
also present with susceptibility to autoimmune 
diseases (i.e., hypothyroidism, type 1 diabetes, 
blood cytopenia, systemic lupus erythematosus, 
vitiligo), enteropathy, cardiac and vascular altera-
tions, bronchiectasis, parodontitis, and failure to 
thrive [5, 6]. Frequent infectious events increase 
the risk of chronic lung disease with a severe 
impact on the quality of life of these patients [7]. 
Chronic-recurrent infections with different pa-
thogens leading to significant morbidity suggest 
combined immunodeficiency, CMC, or Mendelian 
susceptibility to mycobacterial diseases.
Table 3. Primary immunodeficiencies connected with CMC
AD gain-of-function mutation in signal transducer and activator of 
transcription 1 (GOF STAT1)
Severe combined immunodeficiency (SCID)
Combined immunodeficiencies (CID)
Combined immunodeficiency-like dedicator of cytokinesis 8 defi-
ciency (DOCK8)
AD hyper-IgE syndrome (AD-HIES) - signal transducer and activa-
tor of transcription 3 (STAT3) deficiency 
Autoimmune polyendocrine syndrome type 1 (APS-1)
IL-12Rβ1 and IL-12p40 deficiencies
IL17F, IL17RA, IL17RC
Tyrosine kinase 2 (TYK2) deficiency
Caspase recruitment domain 9 (CARD9)
In 2016, an international multicenter study 
examined 274 patients with AD STAT1 GOF mu-
tations. 98% had CMC with a median age at onset 
of 1 year, 74% had bacterial infections with recu-
rrent lobar pneumonia, bronchitis or interstitial 
pneumonia (47%), mainly caused by Streptococ-
cus pneumoniae, Pseudomonas aeruginosa, Ha-
emophilus influenzae and Staphylococcus aureus, 
but only 17 patients (6% of the studied patients) 
had a mycobacterial infection. Bronchiectasis was 
reported in 21% of the 274 patients [13]. On one 
hand, chronic and/or recurrent mucocutaneous 
fungal infections with predominantly C. albicans 
are the major infectious complications in patients 
with STAT1 GOF mutations and generally arise 
in infancy or childhood. On the other hand, the 
recurrence of pulmonary exacerbations frequently 
leads to chronic lung disease with an obstructive 
component as shown by spirometry and progres-
ses to bronchiectasis in childhood. Additionaly 
colonization with Pseudomonas aeruginosa is 
associated with an increased rate of decline in 
lung function and a poorer health-related quality 
of life. That is why careful consideration to the 
possibility of STAT1 GOF mutations should be 
given at the time of CMC diagnosis since they 
are reported to be causative in more than half of 
CMC patients [13]. Still, we should bear in mind 
that these patients may exhibit quite different 
phenotypes, new infections, bronchiectasis, au-
toimmune diseases, malignancies, and aneurysms 
that may emerge gradually with age.
Most patients (70–80%) present with normal 
lymphocyte ratios, immunoglobulin levels, and 
T-cell function despite the high rate of infec-
tions. However, some of the STAT1 GOF mutated 
patients may develop T (CD3+) and, more frequ-
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ently, B (CD19+) cell lymphopenia and hypogam-
maglobulinemia [7, 13], which was also observed 
in a described patient above. In STAT1 GOF pa-
tients, B cell deficiency has been variably reported 
with loss of both switched and unswitched me-
mory B cells with age which, together with a low 
concentration of immunoglobulins, may suggest 
CVID. This disease-bound progressive loss of 
immunologic function despite appropriate treat-
ment (antibacterial, antifungal prophylaxis and 
immunoglobulins substitution) may be another 
possible reason for newly acquired infections as 
well as explain the progression of lung disease, 
which our patient experienced. CVID was also the 
first provisional diagnosis which was given to the 
reported patient after a wide range of immunolo-
gical tests performed for the first time. Recently, 
a STAT1 GOF mutation has been detected in a pa-
tient with a diagnosis of CVID, CMC, and delayed 
neurocognitive development in association with 
Th17 deficiency and low Treg counts [14]. That is 
why most of patients are initially followed with 
various immunological diagnoses such as CID, 
IPEX-like syndrome and even undergo HSCT be-
fore identification of the molecular defect.
It was reported that phenotypic manifesta-
tions of the various STAT1 mutations may differ 
despite the similar molecular and cellular/im-
munological features. However, Uzel et al. [15], 
Soltesz et al. [16], and Sampaio et al. [17] reported 
patients with the same c.1154C>T (p.Thr385Met) 
GOF STAT1 mutation as found in our patient. 
These patients presented with CMC, recurrent 
lower respiratory tract infections, bronchiec-
tasis, and autoimmunities similar to the case 
described here. That being said, more clinical 
information and phenotype–genotype studies are 
required to define clinical phenotype caused by 
AD STAT1 GOF.
Management of patients with STAT1 GOF mu-
tations should target prevention and treatment of 
infections. Prophylactic antimicrobials and IVIG 
are routinely used for this purpose. JAK (Janus 
kinase) inhibitors may potentially be useful in 
some patients as adjunct therapy pending definiti-
ve treatment with HSCT [18]. The fact that CMC 
is heterogeneous, progressive, and unpredictable 
in its course should alert physicians to recognize 
early HSCT as a feasible treatment option to avoid 
severe morbidity and mortality. However, HSCT is 
variable in success because despite being curative, 
it brings with it a significant risk of secondary 
graft failure and death [18]. Thus, the outcome of 
this procedure has not been well established in 
patients with GOF-STAT1 mutations yet.
Conclusion
The clinical presentations of our patient 
with severe, early-onset CID support the notion 
that STAT1 GOF mutations give rise to a wide 
range of disease phenotypes including fungal 
and mycobacterial infections, autoimmunity, 
and combined immunodeficiency. Regardless, 
the most commonly seen presenting symptom 
and clinical presentation is that of progressive 
bronchiectasis. The proper treatment may not 
stop progressive and devastating lung disease, 
which in turn may be a detterent to deciding to 
use HSCT as a treatment option. 
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